Celldex
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Perryville Iii Building suite 220 53 Fro...Phone Number
(908) 454-7120Website
www.celldex.comRevenue
<$5 MillionStock Symbol
CLDXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Celldex
Founded in 1983, Celldex Therapeutics is a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. They are based in Hampton, New Jersey.Explore more
Celldex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celldex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Celldex, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Celldex recently announced quarterly report
Check if Celldex has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Celldex launches new products
Congratulate Masked Content for being promoted to Masked Content at Celldex
Website visits: Recent activity has been detected on your website
Check out if Celldex is spiking on competitors!
Funding: Get notified immidiatlly once Celldex has new funding data
Click to see if Celldex had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Celldex
Find more new buyers
Compare Similar Companies to Celldex
Compare insights from companies similar to Celldex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Celldex is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Celldex is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Celldex.
Celldex Tech Stack
A closer look at the technologies used by Celldex
See more technologies
Most Recent Scoops
Project
Celldex has initiated a Phase III study of barzolvolimab in two forms of inducible urticaria, following Phase II results that demonstrated clinical benefit including high rates of complete response and improvements in quality of life. The study was initiated in late 2025, with enrollment currently underway.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Celldex has reported first-in-human data for CDX-622, a novel bispecific antibody combining mast cell depletion and TSLP inhibition, demonstrating rapid, durable, dose-dependent reductions in serum tryptase and a well-tolerated safety profile across all doses. Currently being studied in asthma, CDX-622 is planned for additional proof-of-concept studies in allergic rhinitis and food allergies.
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Celldex News & Media
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The primary endpoint of the study, the proportion of patients who achieve a four point or greater improvement in WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12, and keyCelldex Announces Planned Transition of Chief Financial Officer
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company’s Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and Mr. Martin will remain as theCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistaCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose lev
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Celldex
Sign Up For FreeTo access detailed company insights
Founded in 1983, Celldex Therapeutics is a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. They are based in Hampton, New Jersey.... Read More
